The news is directly related to Kymera Therapeutics as Credit Suisse reiterated a Neutral rating and maintained a $36 price target. This indicates that the analyst's view on the stock has not changed, and the price target remains the same. As a result, the short-term impact on the stock price is expected to be neutral.